Revvity (NYSE:RVTY) Releases Earnings Results, Beats Estimates By $0.20 EPS

Revvity (NYSE:RVTY) announced its quarterly earnings data on Tuesday. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.20, Zacks reports. The company had revenue of $711.00 million during the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a return on equity of 8.00% and a net margin of 8.26%.Revvity’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 EPS. Revvity updated its FY 2026 guidance to 5.300-5.400 EPS.

Here are the key takeaways from Revvity’s conference call:

• Revvity reported Q2 revenue of $711 million, 3% pro forma organic growth, and adjusted EPS of $1.41, exceeding expectations. Performance benefited from stronger operations, favorable tax timing, and $16 million in tariff refunds.
• The company raised its 2026 outlook to 4%–5% organic growth, approximately 28.7% adjusted operating margin, and adjusted EPS of $5.30–$5.40. Management said the guidance assumes continued improvement in pharma and biotech spending but no further acceleration beyond current trends.
• Diagnostics remained a major strength, growing 11% organically, with reproductive health up in the mid-teens and Immunodiagnostics outside China accelerating to high-single-digit growth. Newborn screening and the Genomics England sequencing contract continued to support results.
• AI-related demand is driving increased orders for high-content screening instruments, particularly the Opera Phenix OptIQ, with double-digit growth and backlog exceeding near-term production capacity. Management expects subsequent reagent pull-through as customers expand their lab-in-the-loop workflows.
• Signals software revenue declined approximately 20% year over year because of contract timing and difficult comparisons, although annualized portfolio value and ARR continued to grow strongly. Management expects a return to double-digit organic growth in the second half, making the recovery dependent on renewals and adoption of new AI-enabled offerings.

Revvity Trading Down 3.6%

RVTY stock opened at $111.06 on Wednesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72. The company has a market capitalization of $12.39 billion, a PE ratio of 53.14, a price-to-earnings-growth ratio of 2.27 and a beta of 1.07. Revvity has a 52 week low of $81.22 and a 52 week high of $118.30. The company’s 50-day simple moving average is $107.16 and its 200 day simple moving average is $99.91.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s payout ratio is presently 13.40%.

Analyst Ratings Changes

Several brokerages recently commented on RVTY. Wolfe Research began coverage on Revvity in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. TD Cowen restated a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Finally, JPMorgan Chase & Co. cut their price target on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $108.36.

Revvity News Summary

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported adjusted earnings of $1.41 per share, exceeding analyst estimates of approximately $1.21-$1.23. Revenue of $711 million also surpassed expectations near $703 million. RVTY Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company raised its fiscal 2026 outlook, projecting earnings per share of $5.30-$5.40, above the $5.25 analyst consensus, and revenue of approximately $2.8-$2.9 billion. Revvity raises annual profit, revenue forecasts on strong diagnostics demand
• Positive Sentiment: Improving demand for diagnostic testing products and drug-development tools, along with wider margins and strong cash flow, supported the better-than-expected quarter and upgraded outlook.
• Neutral Sentiment: Despite the earnings beat, quarterly revenue declined 1.3% year over year. The mixed top-line growth may be tempering investor enthusiasm, particularly after the stock’s recent advance and its relatively high valuation.
• Negative Sentiment: The results did not indicate broad-based revenue growth: the upside was driven primarily by diagnostics strength and operational improvements rather than an overall increase in sales. Investors may therefore be looking for clearer evidence of sustained demand recovery.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Morgan Stanley raised its position in shares of Revvity by 29.6% in the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock valued at $275,202,000 after buying an additional 650,083 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Revvity by 22.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,612,116 shares of the company’s stock valued at $252,727,000 after acquiring an additional 486,159 shares during the last quarter. Neuberger Berman Group LLC raised its position in Revvity by 98.3% during the fourth quarter. Neuberger Berman Group LLC now owns 912,866 shares of the company’s stock valued at $88,320,000 after purchasing an additional 452,419 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Revvity by 5.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company’s stock worth $832,693,000 after purchasing an additional 434,570 shares during the last quarter. Finally, UBS Group AG grew its holdings in shares of Revvity by 22.3% during the 3rd quarter. UBS Group AG now owns 2,179,505 shares of the company’s stock valued at $191,034,000 after purchasing an additional 397,160 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.